Abstract
Background: In recent years, human peripheral blood mononuclear cells (PBMCs) intrauterine perfusion therapy has been widely used prior to embryo transfer for in vitro fertilization (IVF) to improve implantation rates and pregnancy outcomes in patients. However, there are fewer studies on which groups of people are better able to change pregnancy outcomes with PBMCs. In the present study, we discussed the impact of intrauterine perfusion of PBMCs before thawed embryo transfer (FET) on pregnancy outcomes in patients with different BMIs and ages.
Method: This study retrospectively included 563 patients who received PBMCs uterine perfusion therapy at Reproductive Medical Centre, Renmin Hospital of Wuhan University from 2019 to 2021. Grouped according to different BMI and age, analyze whether these factors influence clinical outcomes in patients receiving PBMCs uterine perfusion.
Result: The results showed that the clinical pregnancy and miscarriage rates were significantly higher in the high BMI group than in the normal BMI group (56.52% versus 44.09%, P=0.041). However, the higher rate of miscarriage in the high BMI group (13.04% versus 5.73%, P=0.037) made the difference in live birth rates not particularly significant (32.61% vs. 31.90%, P=?). This situation was significant in the young patients (age≤30ys), for patients who were advanced reproductive age, it was difficult to improve the clinical pregnancy rate by intrauterine administration of PBMCs.
Conclusion: Intrauterine perfusion of autologous PBMCs prior to transfer in patients undergoing FET modifies clinical pregnancy rates in patients with high BMI. This change is more pronounced in younger patients.